| Product Code: ETC6356089 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Belgium`s import shipments of insulin biosimilars saw significant growth with a CAGR of 39.8% from 2020 to 2024. Despite a sharp decline in growth rate in 2024 (-59.2%), the country continued to heavily rely on imports from top exporting countries such as the USA, Austria, Netherlands, Hungary, and the UK. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market, highlighting the dominance of these key exporting nations in supplying insulin biosimilars to Belgium. Further monitoring of market dynamics and competition among exporters will be crucial for stakeholders in the industry.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Belgium Insulin Biosimilars Market Overview |
3.1 Belgium Country Macro Economic Indicators |
3.2 Belgium Insulin Biosimilars Market Revenues & Volume, 2021 & 2031F |
3.3 Belgium Insulin Biosimilars Market - Industry Life Cycle |
3.4 Belgium Insulin Biosimilars Market - Porter's Five Forces |
3.5 Belgium Insulin Biosimilars Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Belgium Insulin Biosimilars Market Revenues & Volume Share, By Indicative, 2021 & 2031F |
3.7 Belgium Insulin Biosimilars Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Belgium Insulin Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Belgium Insulin Biosimilars Market Trends |
6 Belgium Insulin Biosimilars Market, By Types |
6.1 Belgium Insulin Biosimilars Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Belgium Insulin Biosimilars Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 Belgium Insulin Biosimilars Market Revenues & Volume, By Rapid-acting biosimilar, 2021- 2031F |
6.1.4 Belgium Insulin Biosimilars Market Revenues & Volume, By Long-acting biosimilar, 2021- 2031F |
6.1.5 Belgium Insulin Biosimilars Market Revenues & Volume, By Premixed biosimilar, 2021- 2031F |
6.2 Belgium Insulin Biosimilars Market, By Indicative |
6.2.1 Overview and Analysis |
6.2.2 Belgium Insulin Biosimilars Market Revenues & Volume, By Type I Diabetes, 2021- 2031F |
6.2.3 Belgium Insulin Biosimilars Market Revenues & Volume, By Type II Diabetes, 2021- 2031F |
6.3 Belgium Insulin Biosimilars Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Belgium Insulin Biosimilars Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Belgium Insulin Biosimilars Market Revenues & Volume, By Ambulatory Surgical Centers, 2021- 2031F |
6.3.4 Belgium Insulin Biosimilars Market Revenues & Volume, By Others, 2021- 2031F |
7 Belgium Insulin Biosimilars Market Import-Export Trade Statistics |
7.1 Belgium Insulin Biosimilars Market Export to Major Countries |
7.2 Belgium Insulin Biosimilars Market Imports from Major Countries |
8 Belgium Insulin Biosimilars Market Key Performance Indicators |
9 Belgium Insulin Biosimilars Market - Opportunity Assessment |
9.1 Belgium Insulin Biosimilars Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Belgium Insulin Biosimilars Market Opportunity Assessment, By Indicative, 2021 & 2031F |
9.3 Belgium Insulin Biosimilars Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Belgium Insulin Biosimilars Market - Competitive Landscape |
10.1 Belgium Insulin Biosimilars Market Revenue Share, By Companies, 2024 |
10.2 Belgium Insulin Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |